Gilead Sciences, Inc. (GILD): Price and Financial Metrics
Gilead Sciences, Inc. (GILD)
Today's Latest Price: $68.81 USD
Updated Aug 6 6:55pm
Add GILD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GILD Stock Summary
- GILD has a higher market value than 97.97% of US stocks; more precisely, its current market capitalization is $88,909,986,592.
- Gilead Sciences Inc's stock had its IPO on January 22, 1992, making it an older stock than 82.19% of US equities in our set.
- The volatility of Gilead Sciences Inc's share price is greater than that of only 3.39% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are INFI, AKBA, TNAV, MEET, and NOVN.
- Visit GILD's SEC page to see the company's official filings. To visit the company's web site, go to www.gilead.com.
GILD Stock Price Chart Technical Analysis Charts
GILD Price/Volume Stats
| Current price | $68.81 | 52-week high | $85.97 |
| Prev. close | $69.00 | 52-week low | $60.89 |
| Day low | $68.62 | Volume | 8,318,000 |
| Day high | $69.63 | Avg. volume | 16,638,705 |
| 50-day MA | $75.02 | Dividend yield | 3.95% |
| 200-day MA | $71.33 | Market Cap | 86.31B |
Gilead Sciences, Inc. (GILD) Company Bio
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $68.81 | $54.62 | -21% |
We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 43th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Gilead Sciences Inc, consider:
- The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.03%; that's greater than just 24% of US stocks we're applying DCF forecasting to.
- Gilead Sciences Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 20.11% of tickers in our DCF set.
- As a business, Gilead Sciences Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -22% |
| 1% | -22% |
| 2% | -21% |
| 3% | -20% |
| 4% | -19% |
| 5% | -19% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GILD, try ICLR, DGX, EBS, FONR, and NVS.
Loading social stream, please wait...